Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

Bibliography

• Denisov ET, Afanas'ev IB. Oxidation and antioxidants in organic chemistry and biology. Taylor and Francis group, Boca Raton, CRC Press; 2005
   Google Scholar
• Kontoghiorghes GJ. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Front Biosci 2009;E1:161-178
   Google Scholar
• Kolnagou A, Economides CH, Eracleous E, Kontoghiorghes GJ. Long term comparative studies in thalassemia patients treated with deferoxamine or deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols. Hemoglobin 2008;32:41-7
   PubMed Web of Science ®Google Scholar
• Kolnagou A, Michaelides Y, Kontos C, Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone. Hemoglobin 2008;32:17-28
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions. Comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26:553-84
   PubMed Web of Science ®Google Scholar
• Aessopos A, Kati M, Farmaki D, Intensive chelation therapy in beta-thalassemia and possible adverse cardiac effects of desferrioxamine. Int J Haematol 2007;86:212-15
   PubMed Web of Science ®Google Scholar
• Rahi AHS, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol 1986;70:373-81
   PubMed Web of Science ®Google Scholar
• Cases A, Velly J, Sabater J, Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine. Clin Nephrol 1988;29:176-8
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities. Expert Opin Drug Saf 2007;6:235-9
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Eracleous E, Economides CH, Kolnagou A. Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL-670,GT-56-252, L1NAll and their combinations. Curr Med Chem 2005;12:2663-81
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions. Hemoglobin 2006;30:183-200
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ. The study of iron mobilization from transferrin using alpha-ketohydroxy heteroaromatic chelators. Biochim Biophys Acta 1986;869:141-6
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharm Ther 1990;48:255-61
   PubMed Web of Science ®Google Scholar
• Evans RW, Sharma M, Ogwang W, The effect of alpha-ketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today 1992;28(Suppl A):19-23
   Google Scholar
• Pollack S, Aisen P, Lasky FD, Vanderhoff G. Chelate mediated transfer of iron from transferrin to desferrioxamine. Br J Haematol 1976;34:231-5
   PubMed Web of Science ®Google Scholar
• Anonymous. Deferiprone:agranulocytosis and neurological disorders. Prescrire Int 2007;16(88):72
   Google Scholar
• Sofroniadou K, Drossou M, Foundoulaki M, Acute bone marrow aplacia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Saf 1990;5:152-4
   PubMed Web of Science ®Google Scholar
• Nick H, Acklin P, Lattmann R, Development of tridentate iron chelators: from desferriothiocin to ICL-670. Curr Med Chem 2003;10:1065-76
   PubMed Web of Science ®Google Scholar
• Exjade (deferasirox) tablets for oral suspension. Prescribing information. Novartis Pharmaceutical Corp. USA (NDA 21-882). 2006:1-12
   Google Scholar
• Kontoghiorghes GJ. Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide. Hemoglobin 2008;32:608-15
   PubMed Web of Science ®Google Scholar
• Robins-Browne RM, Pipic JK. Desferrioxamine and systemic yersiniosis. Lancet 1983;II:1372
   Google Scholar
• Boelaert JR, Fenves AZ, Coburn JW. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. Am J Kidney Dis 1991;18:660-7
   PubMed Web of Science ®Google Scholar
• Spellberg B, Andes D, Perez M, Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009;53:3122-5. [Epub 2009]
   PubMed Web of Science ®Google Scholar
• Arkadopoulos N, Economou E, Theodoraki K, Iron chelation for attenuation of liver ischemia-reperfusion injury. Abstract book, 19th ICOC, Greece; 2008. p. 15
   Google Scholar
• Polson RJ, Jawad AS, Bomford A, Treatment of rheumatoid arthritis with desferrioxamine. Q J Med 1986;61(236):1153-8
   PubMedGoogle Scholar
• Boddaert N, Le Quan KH, Rotig A, Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007;110:401-8
   PubMed Web of Science ®Google Scholar
• Rajapurkar MM, Beliga R, Shah S. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol 2007;18:57-58A
   Google Scholar
• Rajapurkar MM, Alam MG, Bhattacharya A, Shah S. Novel treatment for diabetic nephropathy. J Am Soc Nephrol 2007;18:329A
   Google Scholar
• Forni GL, Balocco M, Cremonesi L, Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation. Mov Disord 2008;23:904-7
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Hemoglobin 2009;36:386-97
   Google Scholar
• Rafat C, Fakhouri F, Ribeil JA, Fanconi syndrome due to deferasirox. Am J Kidney Dis 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar